{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-014272","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.001587+00:00","generated_at":"2026-06-15T02:45:57.932188+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SAB Biotherapeutics announces Fast Track and Breakthrough Therapy designations for SAB-176 anti-influenza candidate","bullets":["Fast Track Designation granted by FDA for SAB-176, an anti-influenza polyclonal antibody therapy.","Breakthrough Therapy Designation also received for SAB-176, potentially expediting development and review.","Company published an updated corporate strategy presentation on its website discussing these designations and platform.","SAB-176 targets influenza; regulatory milestones may accelerate clinical timeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-014272","json":"https://secwatch.observer/filing/0001437749-23-014272.json","markdown":"https://secwatch.observer/filing/0001437749-23-014272.md","text":"https://secwatch.observer/filing/0001437749-23-014272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923014272/0001437749-23-014272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923014272/sabs20230508_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:45:57.932188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}